VSV-ZEBOV

BIOLOGICAL2 trials

Sponsors

University Hospital, Geneva, University of Oxford

Conditions

Ebola Virus DiseaseEbolavirus Disease

Phase 1

VSV-ZEBOV Geneva Vaccine Trial

CompletedNCT02287480

University Hospital, GenevaEbolavirus Disease

Start: 2014-11-30End: 2016-01-31Updated: 2023-05-10

A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.

University of OxfordEbola Virus Disease

Start: 2014-12-31End: 2016-09-30Target: 40Updated: 2016-04-14

Related Papers

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study.

2018-04-0559 citations

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial

PLoS Medicine2017-10-0668 citations

Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.

2017-06-2135 citations

The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial.

2015-08-04213 citations

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe

New England Journal of Medicine2015-04-02404 citations